Adam R. Johnson
Genentech · 50 works · 3,786 citations · h-index 31
Top works
- Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
- Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity
- Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical Development
- Discovery and Characterization of a Novel Inhibitor of Matrix Metalloprotease-13 That Reduces Cartilage Damage in Vivo without Joint Fibroplasia Side Effects
- Catalytic Activities and Substrate Specificity of the Human Membrane Type 4 Matrix Metalloproteinase Catalytic Domain
- A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors
- Lead Optimization of a 4-Aminopyridine Benzamide Scaffold To Identify Potent, Selective, and Orally Bioavailable TYK2 Inhibitors
- Lead identification of novel and selective TYK2 inhibitors
- Identification of Imidazo-Pyrrolopyridines as Novel and Potent JAK1 Inhibitors
- Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations
- A Rationalization of the Acidic pH Dependence for Stromelysin-1 (Matrix Metalloproteinase-3) Catalysis and Inhibition
- NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus
- In VitroandIn VivoAssays
- Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of Action
- RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases
- Identification of C-2 Hydroxyethyl Imidazopyrrolopyridines as Potent JAK1 Inhibitors with Favorable Physicochemical Properties and High Selectivity over JAK2
- Discovery and Optimization of C-2 Methyl Imidazopyrrolopyridines as Potent and Orally Bioavailable JAK1 Inhibitors with Selectivity over JAK2
- Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc
- The Crystal Structure of the Catalytic Domain of the NF-κB Inducing Kinase Reveals a Narrow but Flexible Active Site
- Reduction in lipophilicity improved the solubility, plasma–protein binding, and permeability of tertiary sulfonamide RORc inverse agonists